# Applied Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/applied-therapeutics

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.appliedtherapeutics.com
- Total disclosed funding: $6.1M
- Latest round: Series A (Jan 26, 2017)
- Investors on record: 4

## About

Based in New York, US, and founded by Shoshana Shendelman (CEO) in 2017, Applied Therapeutics, Inc. operates as a biopharmaceutical company specializing in providing Aldose Reductase Inhibitor (ARI) for diseases. The is trading under the NASDAQ stock exchange under the ticker symbol APLT. In February 2024, the firm raised USD 100 million in PIPE funding led by investors Perceptive Advisors, Janus Henderson Investors, Venrock Healthcare Capital Partners, Adage Capital Management, etc.

Utilizing technological advances and leveraging FDA guidance on biomarkers, Applied Therapeutics aims to expedite the development process, bringing treatments to market for patients with high unmet medical needs. The company's pipeline includes Aldose Reductase Inhibitors (ARI) designed for conditions like Galactosemia, SORD Deficiency, PMM2-CDG, Diabetic Peripheral Neuropathy, Diabetic Rentinopathy, and Diabetic Cardiomyopathy, with ongoing clinical trials demonstrating phase 1 to phase 3 results. Applied Therapeutics’s preclinical pipeline also includes a PI3 kinase inhibitor in development for orphan oncology indications.

The company plans to utilize the February 2024 funding to support its growth and other activities.

## Funding rounds

- Series A, Jan 26, 2017, $6.1M — Alexandria Venture Investments, Syno Capital, E Squared Capital Management, ETP	Global Fund

## Investors

- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Syno Capital (https://capitalatlas.ai/funds/syno-capital) — Series A
- E Squared Capital Management (https://capitalatlas.ai/funds/e-squared-capital-management) — Series A
- ETP	Global Fund — Series A